A new screening method accelerates the discovery of aptamers—short DNA or RNA strands that bind target molecules with high precision—from months to just days. The approach promises to unlock the potential of these synthetic alternatives to antibodies.
Aptamers offer distinct advantages over antibodies: they are more stable, can be produced synthetically, and are chemically modifiable to tune properties. This could enable detection and modulation capabilities that antibodies cannot achieve.
The technique drastically reduces the screening timeline, though details on its mechanism and success rate remain sparse in current reports. No specific speed targets or validation statistics have been disclosed.
If validated, this breakthrough could transform diagnostics and therapeutics, where aptamers may replace antibodies in applications requiring stability or chemical flexibility. Broader adoption will depend on reproducibility across diverse targets.
Experts caution that the method's practical impact hinges on independent replication and scalability beyond the initial demonstrations described in the research.